MRI Imaging in RA and SpA: Dr. Sheila Reyes (@RHEUMarampa ) Dr. Sheila Reyes discusses abstracts #0468 and #0469, presented at the #ACR21 annual meeting. https://t.co/KUoO88dEhQ https://t.co/10R4jC5p0y

• https://bit.ly/3qdfhkF

Ethnic disparities in pts with RA & CVD - paucity of evidence in published lit Need to improve study inclusion, diversity to improve quality of care #ACR21 https://t.co/sWKcHugU9W

In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g. All pts in centre offered Fibroscan liver stifness associations: - age, BMI - not cumulative MTX dose maybe survival bias, but what we're doing now is fine! #ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC

Does concomitant SJS affect tx effectiveness in RA? Abst#0839 suggest yes! ➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores. What's your clinical experience with this? #ACR21 @Rheumnow https://t.co/TIc3raMOSJ

Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE

⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts ➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated! Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q